{
    "id": 21484,
    "fullName": "EPAS1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "EPAS1 over exp indicates an over expression of the Epas1 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2034,
        "geneSymbol": "EPAS1",
        "terms": [
            "EPAS1",
            "bHLHe73",
            "ECYT4",
            "HIF2A",
            "HLF",
            "MOP2",
            "PASD2"
        ]
    },
    "variant": "over exp",
    "createDate": "04/21/2016",
    "updateDate": "07/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8527,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PT2399 variably inhibited tumor growth in clear cell renal cell carcinoma patient-derived xenograft models, with 56% (10/18) models classified as sensitive, and sensitivity was correlated with higher EPAS1 (HIF2A) expression levels (PMID: 27595394).",
            "molecularProfile": {
                "id": 22012,
                "profileName": "EPAS1 over exp"
            },
            "therapy": {
                "id": 4670,
                "therapyName": "PT2399",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6674,
                    "pubMedId": 27595394,
                    "title": "Targeting renal cell carcinoma with a HIF-2 antagonist.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27595394"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5938,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, baseline expression of EPAS1 was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).",
            "molecularProfile": {
                "id": 22012,
                "profileName": "EPAS1 over exp"
            },
            "therapy": {
                "id": 3922,
                "therapyName": "Cediranib + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5202,
                    "pubMedId": 26802156,
                    "title": "A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26802156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22012,
            "profileName": "EPAS1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}